Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2001 October;92(5) > Minerva Medica 2001 October;92(5):325-8

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669

 

Minerva Medica 2001 October;92(5):325-8

    ORIGINAL ARTICLES

Plasma platelet activating factor in nephrotic syndrome

Camici M., Sagripanti A.

Background. The mechanism of proteinuria in nephrotic syndrome is unknown. The plasma behaviour of platelet-activating factor (ng/ml) in nephrotic and normal people has been evaluated.
Methods. A total of 21 patients with nephrotic proteinuria due to glomerular pathology and 20 subjects as normal control people have been studied. Plasma PAF level is evaluated by (125I) RIA Kit (Du Pont NEN).
Results. Patients with glomerular proteinuria appeared to have a significant increase (p<0.05) plasma PAF bioactivity: 116.28±49.6 ng/ml versus 41.4±14.9 ng/ml of normal subjects.
Conclusions. The study shows that PAF may be involved in the mechanism of genesis of human glomerular proteinuria.

language: English


FULL TEXT  REPRINTS

top of page